EMA to provide guidance on avoiding nitrosamines in medicines
The EMA has announced it is drafting guidance on how to avoid the presence of nitrosamines, a probable carcinogenic ingredient, in drugs.
List view / Grid view
The EMA has announced it is drafting guidance on how to avoid the presence of nitrosamines, a probable carcinogenic ingredient, in drugs.
CPhI Worldwide will return for its 30th year on 5-7 November 2019 at Messe Frankfurt in Frankfurt, Germany.
Nucala is the first biologic approved in the US for six- to 11-year-old children with severe eosinophilic asthma by the FDA.
Purdue has filed for bankruptcy protection after a settlement offer from the company over the opioid crisis was rejected by 24 states.
The EMA and the FDA are investigating some ranitidine medicines after they were found to contain NDMA, a probable human carcinogen.
Kenya has become the third African country to introduce the world’s first malaria vaccine into the country, in a phased pilot programme.
The FDA says that even though it recognises the importance of compounded drugs, they also pose a risk to patient safety.
GVOKE injection has received regulatory approval from the FDA for the treatment of severe hypoglycemia in patients with diabetes.
An import of medicinal cannabis from Portugal to Germany signifies the largest quantity ever moved within the EU, highlighting a surge in the medicinal cannabis products market.
The seven centres will aid disease research and clinical development, improving access to patient data for studies.
A settlement has purportedly been agreed between Purdue Pharma and 23 US states to resolve the opioid crisis case against the company.
According to a new report, blockchain technology in the healthcare market size is set to increase exponentially.
The Operation Yellowhammer document has been published, which states that the UK will experience severe delays to the medical supply chain following a no-deal Brexit.
Orphan Drug Designation has been given to sotatercept for the treatment of patients with pulmonary arterial hypertension.
Tepotinib, an investigational therapy for patients with metastatic non-small cell lung cancer has been given Breakthrough Therapy Designation.